Biohaven Pharmaceutical Holding Ltd. (BHVN) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Biohaven Pharmaceutical H... (BHVN)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

35.52

-1.96 (-5.23%)

At close: Jan 14, 2025, 3:59 PM

35.15

-1.05%

After-hours Jan 14, 2025, 07:30 PM EST

undefined% (undefined)

Bid	35.42
Market Cap	3.59B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-9.37
PE Ratio (ttm)	-3.79
Forward PE	n/a
Analyst	Buy

Ask	36.41
Volume	1,132,049
Avg. Volume (20D)	924,677
Open	37.44
Previous Close	37.48
Day's Range	34.39 - 37.44
52-Week Range	26.80 - 62.21
Beta	undefined

About BHVN

Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as re...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Sep 23, 2022

Employees 239

Stock Exchange NYSE

Ticker Symbol BHVN

Website https://www.biohavenpharma.com

Analyst Forecast

According to 13 analyst ratings, the average rating for BHVN stock is "Buy." The 12-month stock price forecast is $60.5, which is an increase of 70.33% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Biohaven Pharmaceutical Holding Ltd. is scheduled to release its earnings on Feb 27, 2025, during market hours.
Analysts project revenue of $9.09M, reflecting a n/a YoY growth and earnings per share of -1.72, making a 6.83% increase YoY.

Why Price Moved

1 month ago · Source

+3.01%

Biohaven shares are trading higher after the compa... Unlock content with Pro Subscription

1 month ago · Source

+5.45%

Biohaven shares are trading higher after RBC Capital reiterated with an Outperfom rating on the stock and raised its price target from $58 to $61.

News

4 weeks ago · benzinga.com

Biohaven Advances in Immunotherapy: Significant IgG Reduction Achieved with BHV-1300, Gains Analyst Approval

On Monday, Biohaven Ltd. BHVN revealed clinical and regulatory milestones across its proprietary Molecular Degrader of Extracellular Proteins (MoDE) platform and its glutamate modulation and ion chann...

1 month ago · seekingalpha.com

Biohaven's Revenue Path: SCA And Obesity Therapies

Biohaven's pipeline progression includes Troriluzole for spinocerebellar ataxia [SCA], which has shown a 50-70% reduction in disease progression over three years. BHV-2100, a non-opioid migraine treat...

1 month ago · benzinga.com

Scholar Rock Stock Jumps As Rival Biohaven's Muscle-Wasting Drug Flunks Pivotal Study

On Monday, Biohaven Ltd. BHVN updated the taldefgrobep alfa development programs in Spinal Muscular Atrophy (SMA) and obesity.

1 month ago · benzinga.com

Cassava Sciences, Biohaven And Other Big Stocks Moving Lower In Monday's Pre-Market Session

U.S. stock futures were higher this morning, with the Dow futures gaining more than 300 points on Monday.

1 month ago · reuters.com

Biohaven's spinal muscular atrophy drug fails to meet main goal in study

Biohaven said on Monday its experimental treatment for spinal muscular atrophy, a rare nervous system dosorder, helped improve patients' motor function in a late-stage study, but failed to achieve sta...